The researchers reviewed data on over 117,000 patients with diabetes diagnosis who were prescribed semaglutide (GLP-1), empagliflozin, exenatide, tirzepatide, or insulin
That makes the latest research all the more exciting: Early, observational work in postmenopausal women suggests that pairing GLP-1s with hormone replacement therapy may result in greater weight loss than GLP-1s alone
GI Symptom Screen : Document any active nausea, vomiting, or diarrhea that may indicate clinical dehydration
2005 Feb 15;38(4):499-506
Jumping to high doses too quickly dramatically increases nausea, vomiting, and other GI symptoms without producing faster weight loss
and (6) ability to provide informed consent, assessed through preoperative neuropsychological evaluation